FibroBiologics has initiated a clinical trial for CYWC628, a fibroblast-based therapy aimed at treating diabetic foot ulcers (DFUs), a condition affecting over 33 million people globally with limited effective treatments. This milestone marks a shift from development to clinical execution, with patient enrollment starting in Q2 2026 and topline data expected by the end of 2026. The company also continues advancing other programs in multiple sclerosis, psoriasis, and immune function restoration, backed by a strong patent portfolio and sufficient capital to support ongoing trials. This progress reflects FibroBiologics' strategy to address chronic diseases through innovative cell therapies.
Adobe's Chief People Officer, Gloria Chen, sold 1,607 shares of Adobe stock to cover tax withholding related to her compensation. This transaction is a routine financial move tied to employee stock benefits and does not indicate any change in company...
Bank of Marin Bancorp reported a strong second quarter with earnings per share of $0.58, beating analyst estimates by over 11% and more than doubling last year's EPS of $0.29. The bank's revenue rose 16.8% year-over-year to $34.1 million, surpassing ...
LVMH is set to report Q3 earnings with an expected EPS of $2.47 and revenue of $22.02 billion, following strong Q2 sales of $22.20 billion driven by U.S. demand. The luxury goods company, which owns brands like Louis Vuitton and Dior, shows a P/E rat...
Sierra Bancorp reported Q2 earnings per share (EPS) of $0.77, below analyst expectations of $0.89, and revenue of $38.98 million, missing the forecast of $39.59 million. The EPS slightly declined from $0.78 a year ago, indicating a small year-over-ye...
Navitas Semiconductor, a maker of AI data center power chips, has seen its stock fall 40% this month, making its upcoming earnings report crucial. Analysts expect a loss of $0.04 per share and revenue near $10 million, reflecting a 31.3% decline from...
